» Articles » PMID: 23370537

Chloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 Domain-mediated PUMA Degradation

Overview
Publisher Elsevier
Specialty Dermatology
Date 2013 Feb 2
PMID 23370537
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The Bcl homology-3 (BH3)-only protein p53 upregulated modulator of apoptosis (PUMA) counters Bcl-2 family anti-apoptotic proteins and promotes apoptosis. Although PUMA is a key regulator of apoptosis, the post-transcriptional mechanisms that control PUMA protein stability are not understood. We show that a lysosome-independent activity of chloroquine (CQ) prevents degradation of PUMA protein, promotes apoptosis, and reduces the growth of melanoma xenografts in mice. Compared with wild-type PUMA, a BH3 domain-deleted PUMA protein showed impaired decay in melanoma cells. Fusion of the BH3 domain to a heterologous protein led to its rapid turnover that was inhibited by CQ. Although both CQ and inhibitors of lysosomal proteases stalled autophagy, only CQ stabilized PUMA protein and promoted apoptosis. Our results reveal a lysosomal protease-independent activity of CQ that selectively promotes apoptosis in melanoma cells.

Citing Articles

Emerging dimensions of autophagy in melanoma.

Pangilinan C, Klionsky D, Liang C Autophagy. 2024; 20(8):1700-1711.

PMID: 38497492 PMC: 11262229. DOI: 10.1080/15548627.2024.2330261.


Chloroquine and Chemotherapeutic Compounds in Experimental Cancer Treatment.

Agalakova N Int J Mol Sci. 2024; 25(2).

PMID: 38256019 PMC: 10815352. DOI: 10.3390/ijms25020945.


Potential effect of chloroquine and propranolol combination to treat colorectal and triple-negative breast cancers.

Anselmino L, Baglioni M, Reynoso G, Rozados V, Scharovsky O, Rico M Sci Rep. 2023; 13(1):7923.

PMID: 37193722 PMC: 10188563. DOI: 10.1038/s41598-023-34793-6.


Autophagy Paradox: Strategizing Treatment Modality in Melanoma.

Pangilinan C, Xu X, Herlyn M, Liang C Curr Treat Options Oncol. 2023; 24(2):130-145.

PMID: 36670319 PMC: 9883356. DOI: 10.1007/s11864-023-01053-8.


Melanogenesis and the Targeted Therapy of Melanoma.

Li C, Kuai L, Cui R, Miao X Biomolecules. 2022; 12(12).

PMID: 36551302 PMC: 9775438. DOI: 10.3390/biom12121874.


References
1.
Maclean K, Dorsey F, Cleveland J, Kastan M . Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2007; 118(1):79-88. PMC: 2148253. DOI: 10.1172/JCI33700. View

2.
Sheen J, Zoncu R, Kim D, Sabatini D . Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell. 2011; 19(5):613-28. PMC: 3115736. DOI: 10.1016/j.ccr.2011.03.012. View

3.
Yu J, Zhang L, Hwang P, Kinzler K, Vogelstein B . PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001; 7(3):673-82. DOI: 10.1016/s1097-2765(01)00213-1. View

4.
Lee J, Herlyn M . MEK'ing the most of p53 reactivation therapy in melanoma. J Invest Dermatol. 2012; 132(2):263-5. DOI: 10.1038/jid.2011.362. View

5.
Gomes N, Espinosa J . Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding. Genes Dev. 2010; 24(10):1022-34. PMC: 2867207. DOI: 10.1101/gad.1881010. View